Theramex, a global pharmaceutical company specializing in women’s health, has entered into a licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialize and launch Linzagolix, an oral GnRH antagonist. The launch will be for global markets outside of the U.S., Canada, and Asia.
Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids. Linzagolix is also in development as a potential treatment for endometriosis-associated pain. Linzagolix is not currently approved for any indication anywhere in the world.
“ObsEva is an ideal partner for Theramex given their focus on developing novel treatments to meet unmet medical needs of women suffering from uterine fibroids, endometriosis, and pre-term labor. Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery. By licensing Linzagolix we can potentially offer a new treatment option for physicians in managing women with uterine fibroids to provide symptomatic relief and delay or avoid surgery. Additionally, we will continue to work with our partner ObsEva for follow-on indications, such as endometriosis, another area of women’s health with limited treatment options. This marks an important therapeutic extension for Theramex to widen our portfolio and provide gynecologist’s support for unmet medical needs,” said Robert Stewart, Theramex CEO.